Effect of Neprilysin on Glucagon-Like Peptide-1 in Patients With Type 2 Diabetes (NEPT2D)
The Effect of Neprilysin on Plasma Concentrations of Glucagon-Like Peptide-1 in Patients With Type 2 Diabetes
Sponsor: Hvidovre University Hospital
This PHASE4 trial investigates Type2 Diabetes and is currently completed. Hvidovre University Hospital leads this study, which shows 8 recorded versions since 2019 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jun 2021 — Jul 2024 [monthly]
Completed PHASE4
Status: Recruiting → Completed
-
Jan 2021 — Jun 2021 [monthly]
Recruiting PHASE4
-
Apr 2020 — Jan 2021 [monthly]
Recruiting PHASE4
▶ Show 3 earlier versions
-
Feb 2020 — Apr 2020 [monthly]
Recruiting PHASE4
-
May 2019 — Feb 2020 [monthly]
Recruiting PHASE4
-
Apr 2019 — May 2019 [monthly]
Recruiting PHASE4
First recorded
Jan 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hvidovre University Hospital
- University of Copenhagen
For direct contact, visit the study record on ClinicalTrials.gov .